Sign Up to like & get
recommendations!
0
Published in 2020 at "International Medical Case Reports Journal"
DOI: 10.2147/imcrj.s229080
Abstract: Background Crizotinib is the first tyrosine kinase inhibitor approved for the treatment of anaplastic lymphoma kinase (ALK) rearranged non-small cell lung cancer (NSCLC). An increased incidence of renal cysts has been described during the crizotinib…
read more here.
Keywords:
renal hepatic;
hepatic cysts;
treatment;
caused crizotinib ... See more keywords